Skip to content

Novel germline JAK2 mutation linked to progression to MF in MPN
Andrew Kuykendall, MD, discusses updated data from the RALLY-MF trial
ERNEST-3 analysis characterizes prevalence of cytopenic MF and treatment trends
Study identifies 4 clinically distinct myelofibrosis subtypes that have different survival prognoses
Study identifies new standard of care for relapsed or refractory MM in the second line and beyond

Insider Reader Survey

Join SOHO

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

Multiple Myeloma News

FDA panel votes 6-2 in favor of daratumumab for high-risk smoldering multiple myeloma

by Leah Sherwood
May 22, 2025
0 Comments

Multiple Myeloma

New genomic test provides a less invasive option for myeloma diagnosis

by sohonews
April 30, 2025
0 Comments

Cellular Therapy 2025 AACR Annual Meeting Multiple Myeloma

Trispecific therapy ISB 2001 active in ongoing early myeloma trial

by Leah Sherwood
April 29, 2025
0 Comments

Time for Phase 2. Hand holds a cube with number '2'. Word 'Phase 2'. Beautiful black background. Business concept. Copy space.

Multiple Myeloma News

Early intervention with daratumumab for smoldering myeloma may delay disease progression

by SOHO Insider Editors
April 25, 2025
0 Comments

Multiple Myeloma News

Real-world data support efficacy of IsaPd triplet in relapsed/refractory myeloma

by SOHO Insider Editors
April 22, 2025
0 Comments

Lymphoma Multiple Myeloma News

Spain’s POC manufacturing model reimagines CAR-T delivery

by Leah Sherwood
April 20, 2025
0 Comments

Multiple Myeloma News

ISAF approves equecabtagene autoleucel for relapsed or refractory multiple myeloma

by SOHO Insider Editors
April 10, 2025
0 Comments

Cellular Therapy 2025 EBMT Annual Meeting Multiple Myeloma News

CARTITUDE-4: Nearly 75% of patients alive 3 years after cilta-cel treatment for myeloma

by SOHO Insider Editors
April 9, 2025
0 Comments

Multiple Myeloma

Dr. Lipof discusses Myeloma Action Month

by Leah Sherwood
March 30, 2025
0 Comments

Leukemia Lymphoma Multiple Myeloma News

Is it time to revisit MRD’s role in relapse detection?

by SOHO Insider Editors
March 25, 2025
0 Comments

1
...
6
7
8
9
10

Top Categories

Cellular Therapy

74

Leukemia

113

Lymphoma

128

Multiple Myeloma

98

Myelodysplastic Syndromes

39

Myeloproliferative Neoplasms

28

POPULAR NEWS

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

About Us

Categories

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Contact Info

Multiple Myeloma News

FDA panel votes 6-2 in favor of daratumumab for high-risk smoldering multiple myeloma

New genomic test provides a less invasive option for myeloma diagnosis

Trispecific therapy ISB 2001 active in ongoing early myeloma trial

Early intervention with daratumumab for smoldering myeloma may delay disease progression

Real-world data support efficacy of IsaPd triplet in relapsed/refractory myeloma

Spain’s POC manufacturing model reimagines CAR-T delivery

ISAF approves equecabtagene autoleucel for relapsed or refractory multiple myeloma

CARTITUDE-4: Nearly 75% of patients alive 3 years after cilta-cel treatment for myeloma

Dr. Lipof discusses Myeloma Action Month

Is it time to revisit MRD’s role in relapse detection?

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Categories

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Recent Posts

Novel germline JAK2 mutation linked to progression to MF in MPN

Andrew Kuykendall, MD, discusses updated data from the RALLY-MF trial

ERNEST-3 analysis characterizes prevalence of cytopenic MF and treatment trends

About Us

Categories

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Contact Info

Follow Us

Multiple Myeloma News

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms